Background Alzheimer's disease is a multifactorial disorder for which there is no disease-modifying treatment yet. CB2 receptors have emerged as a promising therapeutic target for Alzheimer's disease because they are expressed in neuronal and glial cells and their activation has no psychoactive effects. Objective The aim of this study was to investigate whether activation of the CB2 receptor would restore the aberrant enhanced proliferative activity characteristic of immortalized lymphocytes from patients with late-onset Alzheimer's disease. It is assumed that cell-cycle dysfunction occurs in both peripheral cells and neurons in patients with Alzheimer's disease, contributing to the instigation of the disease.
Introduction
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is a neurodegenerative disorder marked by progressive impairment of cognitive ability. The neuropathological hallmarks for AD are b-amyloid (Ab) plaques, neurofibrillary tangles, and regionalized neuronal loss. The causes of the disease are largely unknown but many factors are implicated, including toxic effects of aggregated amyloid and tau proteins [1, 2] , inflammation [3] and oxidative damage, [4] and cell-cycle disturbances [5] [6] [7] .
With increasing life expectancy across the world, dementia is a rapidly growing socioeconomic and medical problem. There are no effective disease-modifying drugs currently available. Drug development for AD has proven to be very difficult. Five drugs are approved for the treatment of AD including four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an Nmethyl-D-aspartate receptor antagonist (memantine) [8, 9] . Moreover, in recent years, all clinical trials with new drugs have failed. Therefore, it is a priority to explore new alternatives for the development of new drugs.
Alzheimer's disease has a multifactorial nature, where interrelated events result in the formation of plaque and neurofibrillary tangles, cholinergic deficit, and neuronal loss. Current therapeutic strategies are directed to address multiple etiological targets [10] . In this regard, we have designed and synthesized new indazole ethers that possess different activities as CB2 agonists and inhibitors of butyrylcholinesterase (BuChE) and b-secretase-1 [11] .
In recent years, there has been a growing interest in the use of cannabinoids for patients with AD because the cannabinoid system is dramatically altered in the AD brain [12] . Cannabinoid compounds could act on different pharmacological targets, as well as interacting with the endocannabinoid system. CB2 receptors were first found in peripheral organs such as the spleen or thymus, as well as in macrophages, B cells, and natural killer cells [13] ; however, increasing evidence during the last decade supports the involvement of CB2 receptors and signaling in neurogenesis, axon guidance, and neuronal excitability [14] [15] [16] [17] . Furthermore, deletion of CB2 receptors in the mouse hippocampus has been found to be associated with deficits in memory and synaptic plasticity [18] . Therefore, it is believed that non-psychoactive CB2 receptors could have potential as therapeutic target for neurodegenerative disorders including AD (reviewed in [19] ).
It is well known that AD is characterized by marked cholinergic dysfunction [20] . Depletion of acetylcholine together with a significant reduction in acetylcholinesterase activity and increased BuChE activity are observed in the cortex and hippocampus of patients with AD [21] . These changes are thought to contribute to the loss of memory and cognition during disease progression. In addition, BuChE has been associated with Ab plaques and neurofibrillary tangles [22, 23] . These features emphasize the potential of BuChE as a therapeutic target for AD [24] .
The present work was undertaken to explore the potential of a new CB2 agonist, with the additional property of BuChE activity inhibition, which could restore the observed pathological features of peripheral cells from patients with late-onset AD. Our previous work highlighted the role of Ca 2? /calmodulin (CaM)-dependent activation of PI3K/Akt in controlling cell proliferation of immortalized lymphocytes from patients with AD [25, 26] . It was demonstrated that the cell-cycle regulatory failure observed in AD lymphoblasts resulted from enhanced degradation of the CDK inhibitor p27, with the concomitant stimulation of phosphorylation of the pRb family of proteins and thus favoring the progression of the cell cycle at the G1/S checkpoint [27] . It was suggested that these cell cyclerelated alterations could have pathogenic significance in AD, as it is believed that unscheduled cell-cycle entry underlies neuronal loss in neurodegenerative disorders [7, [28] [29] [30] . The re-entry of quiescent neurons into the cell cycle may result in a mitotic failure and cell death [5, 6, 31] . Moreover, lymphoblastoid cell lines from patients with AD have been previously used as a platform to test the therapeutic potential of certain drugs [32] [33] [34] . Here, we report the ability of one in-house-designed CB2 agonist with additional cholinergic activity, in normalizing the aberrant proliferation and signaling of lymphoblasts from patients with AD. In addition, this compound shows neuroprotective effects against Ab-induced cell death in primary rat cortical neurons and human neuroblastoma SH-SY5Y cells.
Methods

Materials
All components for cell culture were obtained from Invitrogen (Carlsbad, CA, USA). Polyvinylidene difluoride membranes for western blots were purchased from Bio-Rad (Richmond, CA, USA). The enhanced chemiluminescence system was from Amersham (Uppsala, Sweden). All other reagents were of molecular grade. Antibodies against bactin (sc-81178), a-tubulin (B-5-1-2) sc-23948, pRb (sc-500), p27 (sc-528), pCaMKII (Thr286) (sc-12886-R), Akt (C-20) (sc-1618), and CB2 (3C7) (sc-293188) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). The rabbit polyclonal antibody against human phospho-Akt (Ser473) #9271 was obtained from Cell Signaling (Beverly, MA, USA). The rabbit polyclonal antibody against human NeuN (ABN78) was obtained from Merk Millipore (Darmstadt, Germany). The rabbit polyclonal antibody against the human glial fibrillary acidic protein (GFAP; Z0334) was obtained from Dako (Agilent, Santa Clara, CA, USA).
Compound Preparation
The CB2 agonist, PGN33 [1-(2-diisopropilaminoethyl)-3-(4-metoxybencyloxy) indazole] was synthesized as previously described [11] . PGN154, a potent inhibitor of BuChE (IC 50 0.15 ± 0.02 lM) was synthesized in our group (PCT/ES2016/070906, 2016). Table 1 provides the chemical details of PGN33 together with effective permeability values, which predict its ability to cross the blood-brain barrier [35] . The effect of PGN33 on BuChE activity was assessed using BuChE from human serum (3 units/mg of protein) and 0.4 mM of butyrylthiocholine as the substrate in Ellman's reagent [5,5-dithio-bis (2-nitrobenzoic acid)] as described [11] . The values of IC 50 were calculated by ultraviolet spectroscopy from the absorbance changes at 412 nm. Experiments were performed in triplicate. The commercial CB2 agonist JWH133 was from Tocris Cookson Ltd. (Bristol, UK) and the CB2 antagonist AM630 was provided by Sigma (Alcobendas, Spain). Compounds were dissolved in 100% dimethyl sulfoxide as a 10-mM stock and diluted with phosphate-buffered saline (Invitrogen) to their final concentrations. Ab 42 powder (AnaSpec, Inc., San Jose, CA, USA) was dissolved in acetic acid (0.1 M) obtaining a 2-lg/lL stock. Then, Ab 42 was oligomerized in no phenol red Dulbecco's Modified Eagle Medium for 24 h at 4°C. The final concentration in the rat primary cortical neuron cultures was 5 lM. All dilutions of stock were prepared fresh before addition to the culture medium. All vehicles were confirmed to have no biological effects. Human neuroblastoma (SH-SY5Y) cells were purchased from the European Collection of Cell Cultures (Health Protection Agency, Salisbury, UK), and were propagated in Dulbecco's Modified Eagle Medium containing L-glutamine (2 mM), 1% non-essential amino acids, 1% penicillin/streptomycin, and 10% fetal bovine serum under humidified 5% CO 2 and 95% air. On attaining semiconfluency, cells were pre-treated with PGN33 and/or AM630 during 1 h before the addition of Ab. Four hours later, cultures were processed for cell viability assay or western blotting. 50 values (mean ± standard error of the mean) were determined from three different experiments using 0.5 mM of butyrylthiocholine as the substrate [11] . BBB prediction was estimated as previously reported [35] 
Cell Lines
Rat Primary Neuronal Cultures
Pregnant Wistar rats (3-5 months old) were obtained from the inbred colony of the Research Institute, Hospital Doce de Octubre, Madrid, Spain. Primary cortical neuronal cultures were prepared from rat embryos (E15-16) according to methods described previously [37, 38] . Then, 3 9 10 4 cells per well were plated in pre-treated poly-D-lysine-coated 96-well plates for cell viability assay using 3-
0 -deoxyuridine incorporation into DNA as previously described, [39, 40] respectively. For immunoblotting 4 9 10 5 cells per well were plated in pretreated poly-D-lysine-coated 6-well plates. Cells were maintained at 37°C in a 5% CO 2 humidified atmosphere in Neurobasal A medium (Thermo Scientific, Madrid, Spain) containing 2 mM of L-glutamine, and 10% B27 Supplement (Thermo Scientific, Madrid, Spain). Cortical neurons were treated with 5 lM of Ab 42 for 24 h and pre-treated or not for 1 h with increasing concentrations of PGN33. The concentration of Ab 42 (5 lM) was chosen on the basis of previous studies in our and other laboratories [41, 42] . After treatment, cultures were processed for a cell viability assay, 5-bromo-2 0 -deoxyuridine incorporation, or immunoblotting. All animals were handled and cared for according to the Council Directive 2010/63/UE of 22 September, 2010.
Determination of Cell Proliferation, Cell
Viability, and Cell Cycle
Cell proliferation was determined by total cell counting, using a TC10 TM Automated Cell Counter (Bio-Rad Laboratories, S.A., Madrid, Spain). Epstein-Barr virus-immortalized lymphocytes from control patients and patients with AD were seeded at an initial cell concentration of 1 9 10 6 cells 9 mL -1 and enumerated every day thereafter for 3 days. Cells failing to exclude Trypan blue were considered nonviable. 5-Bromo-2 0 -deoxyuridine incorporation was determined in a rat primary neuronal culture method using an enzyme-linked immunoassay kit procured from Roche (Madrid, Spain). Cell viability was determined by the MTT assay, as previously described [39] . Cell survival was normalized to untreated controls and is presented as a percentage. Cell-cycle analysis was performed using a standard method [43] . Cells were fixed in 75% ethanol for 1 h at room temperature. Subsequent centrifugation of the samples was followed by incubation of cells in phosphate-buffered saline containing 1 lg/mL of RNase at room temperature for 20 min and staining with propidium iodide (25 lg/mL). Cells were analyzed in an EPICS-XL cytofluorimeter (Coulter Científica, Móstoles, Spain). Estimates of cell-cycle phase distributions were obtained by computer analysis of DNA content distributions.
Immunoblotting Analysis
Cells were harvested, washed in phosphate-buffered saline, and then lysed in ice-cold lysis buffer as previously described [40] . Protein estimation was determined by the Pierce BCA Protein Assay kit (Thermo Scientific, Madrid, Spain). Then, 50-100 lg of protein was fractionated on a sodium dodecyl sulfate polyacrylamide gel, and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA) and immunodetected as described previously [40] . Primary antibodies were used at the following concentrations: anti-pRb (1:1000); anti-p27 (1:500); anti-phospho-Akt (Ser473) (1:1000); anti-Akt (1:1000); anti-b-actin (1:500); anti-phospho-CaMKII (Thr286) (1:1000); anti-CaMKII (1:500); anti-CB2 (1:200) anti-NeuN (1:1000); anti-GFAP (1:1000). The relative band intensities were quantified using Image Studio Lite software (LI-COR Biotechnology, Lincoln, NE, USA).
Statistical Analysis
Statistical analyses were performed with Graph Pad Prism 6 (La Jolla, CA, USA). All the statistical data are presented as mean ± standard error of the mean. All the experiments were replicated at least three times. Normality was checked with the Shapiro-Wilk test. Parametric tests were therefore used in the statistical analysis. Statistical significance was Values are mean ± standard deviation AD patients with a diagnosis of probable Alzheimer's disease, Control healthy control individuals with no sign of neurological disease estimated by both one-and two-way analysis of variance followed by the Bonferroni's test for multiple comparisons. A value of p \ 0.05 was considered significant.
Results
Proliferative Activity of Lymphoblasts from Control Subjects and Patients with Alzheimer's Disease
The effect on proliferation of the CB2 agonist PGN33 was determined using the colorimetric MTT assay. First, a doseresponse curve was evaluated in lymphoblasts from patients with late-onset AD compared with control cells for 72 h. As shown in Fig. 1a , PGN33 reduced the viability of AD lymphoblasts, in a dose-dependent manner, while the viability of control cells was found affected only at the highest concentration of PGN33 (Fig. 1a) . Then, the effect on proliferation was analyzed using the 5-lM concentration in lymphoblasts from control patients and patients with AD by total cell counting excluding Trypan blue. Figure 1b shows a time course analysis of the proliferative activity of control and AD lymphoblasts in the absence and presence of PGN33. In agreement with previous reports, [26, 27] AD lymphoblasts showed higher proliferative activity than control cells. The CB2 agonist PGN33 selectively prevented the enhanced stimulation of proliferation of AD lymphoblasts, showing no significant effects on control cells (Fig. 1b) . Figure 1c shows that the proliferation of lymphoblasts from patients with AD was not affected by the degree of disease progression. Cell lines from patients with mild, moderate, or severe AD showed similar rates of cell growth, with no significant differences in the efficacy of PGN33 in blocking cell proliferation (Fig. 1c) . The effects of PGN33 inhibiting the proliferation of AD lymphoblasts were comparable to that induced by the reference CB2 agonist JWH133 (Fig. 2) . Moreover, the effect of PGN33 was prevented by the specific CB2 antagonist, AM630. The addition of the potent BuChE inhibitor, PGN154 (IC 50 0.15 ± 0.02 lM), which does not bind to CB2 receptors (PCT/ES2016/070906, 2016), had no appreciable effects on the proliferative activity of AD lymphoblasts (Fig. 2) . The above observations suggest that the antiproliferative effect of PGN33 requires CB2 receptor activation, but is independent of BuChE activity.
Effects of CB2 Agonists on the Downstream Signaling Pathway
We first analyzed the effects of perturbing the CB2 receptor signaling by using pertussis toxin to inhibit the coupling of the receptor with G i/0 proteins, and the CaM antagonist, calmidazolium or the specific PI3K/Akt inhibitor Ly294002, as the Ca 2? /CaM/PI3K/Akt was previously found to be increased in AD lymphoblasts [27] . Table 3 shows the influence of these effectors on cell viability in comparison with the CB2 agonist PGN33. The inhibition of cell survival by pertussis toxin or Ly294002 was approximately 25% in control and AD cells. In contrast, and in agreement with previous reports from this laboratory [26] , the antagonist of CaM, calmidazolium, exclusively inhibited the proliferation of lymphoblasts from patients with AD. The CB2 agonist PGN33 mimicked the effects of the CaM antagonist ( Table 3 ), suggesting that PGN33 prevents the Ca 2? /CaM-mediated stimulation of PI3K/Akt.
The effects of PGN33 on CaM or PI3K/Akt signaling were assessed in control and AD lymphoblasts by monitoring the phosphorylation status of CaMKII or Akt by using phospho-specific anti-CaMKII or anti-Akt antibodies. Cells were pre-incubated with the corresponding drug 30 min before serum stimulation, and the levels of the phosphorylated proteins were determined 24 h later. As expected, lymphoblasts from individuals with AD showed increased levels of pCaMKII and pAkt, thus indicating higher activity of these two kinases in comparison with that of control cells. Incubation of cells with PGN33 blunted the enhanced phosphorylated levels of Akt and CaMKII characteristic of AD lymphoblasts without affecting the phosphorylation of these proteins in control cells (Fig. 3a) . These results suggest that PGN33 prevents, rather than inhibits, the activation of the PI3K/Akt pathway. We next sought to check whether PGN33 is effectively blocking the increase in the levels of phosphorylated pRb. Fig. 2 Antiproliferative effects of CB2 receptor activation were prevented by the specific CB2 antagonist AM630. Immortalized lymphocytes from control subjects and patients with Alzheimer's disease (AD) were seeded at an initial density of 1 9 10 6 9 mL -1 in the absence or in the presence of PGN33 (5 lM), with and without the CB2 antagonist AM630 (5 lM). In addition, the effects of equal concentration of the commercial CB2 agonist JWH133 and the non-CB2 agonist, inhibitor of BuChE PGN154 were determined 72 h after their addition. The box plot represents the proliferative activity of control (white) and AD lymphoblasts (black). BuChE butyrylcholinesterase. ***p \ 0.001 significantly different from control cells; p \ 0.05, p \ 0.01, and p \ 0.001, significantly different from untreated AD cells, respectively shows how this treatment was effective in decreasing the phosphorylation of pRb in AD lymphoblasts up to levels similar to those of control cells. We did not detect any differences in either levels of these two proteins or in the effects of PGN33, depending on disease severity (not shown).
Increased pRb levels in AD lymphoblasts could be the consequence of reduced cellular content of the CDK inhibitor p27, which in turn allows cell-cycle progression [27, 32] . Indeed, the PGN33-induced inhibition of cell proliferation and pRb phosphorylation in AD lymphoblasts was accompanied by increased levels of p27 protein (Fig. 4) .
Neuroprotective Effects of PGN33 on b-
Amyloid-Induced Death in Alzheimer's Disease Neuronal Models
The above results obtained in lymphoblastoid cell lines were then validated in neuronal models of AD disease. We assessed the expression levels of CB2 receptors in SH-SY5Y and rat primary neuronal cultures by western blotting (Fig. 5a ) using human lymphoblasts lysates as the control. A prominent band of approximately 45 kDa was found in the three types of cells. The expression of CB2 receptors was found to be higher in lymphocytes than in neuronal cells (Fig. 5a ). Levels of neuronal and glial markers NeuN and GFAP indicated that the primary culture contained mostly post-mitotic neurons (Fig. 5a) . Figure 5b shows the effect of PGN33 on the survival of Abtreated human neuroblastoma SH-SY5Y cells. b-Amyloid induced the death of SH-SY5Y cells (Fig. 5b) , and PGN33 reduced cell death significantly (Fig. 5b) . To assess the involvement of CB2 receptors in this effect, cells were pretreated with PGN33 in the presence of increasing concentrations of the selective CB2 antagonist AM630. The antagonist had no effect in control cells, but significantly reduced, in a concentration-dependent manner, the survival of neuroblastoma cells treated with Ab and PGN33 (Fig. 5b) , suggesting that the neuroprotective effect of PGN33 on Ab-induced cell death is mediated by CB2 receptors. Then, we evaluated the effects of PGN33 in post-mitotic neuronal cells. For these experiments, rat primary neuronal cultures were pre-treated with increasing concentrations of PGN33 for 1 h before Ab exposure, and cell viability was analyzed 24 h later by an MTT assay. As shown in Fig. 5c , PGN33 prevented the cell death induced by Ab in these non-dividing neurons, in a dose-dependent manner. Maximal effects were found at a 5-lM Ab concentration. It was previously reported that Ab treatment activates the cell cycle in primary cultures of rat cortical neurons [44] . For this reason, we determined the effects of Ab on the rate of 5-bromo-2 0 -deoxyuridine incorporation into the DNA, in Fig. 3 Effects of the CB2 agonist PGN33 on the activation of PI3K/Akt and CaMKII. Immortalized lymphocytes from control subjects and patients with Alzheimer's disease (AD) were seeded at an initial density of 1 9 10 6 9 mL
, and were incubated in an RPMI medium containing 10% fetal bovine serum in the absence or in the presence of the CB2 agonist PGN33 (5 lM). Cell extracts were prepared 24 h after drug administration to determine CaMKII and PI3K/Akt activation by western blot using phospho-specific antibodies anti-CaMKII and Akt. Representative immunoblots are shown. The densitometric data represent the mean ± standard error of the mean of four different experiments. **p \ 0.01 and ***p \ 0.001, significantly different from control cells; p \ 0.05 and p \ 0.01, significantly different from untreated AD cells the absence or presence of PGN33. Figure 5d shows that indeed PGN33 was able to partially block the increase in DNA synthesis induced by Ab. Additionally, the cellular levels of pRb and p27 proteins were determined. We found that PGN33 blocked the Ab-induced increased phosphorylation of pRB by restoring the normal levels of p27 (Fig. 5e ).
Discussion
There is growing evidence of the potential of CB2 agonists in the treatment of neurodegenerative diseases including AD [19] . CB2 receptors appear to be increased in the brains of patients with neurodegeneration [45] and CB2 agonists have shown neuroprotective effects in several models of brain injury [46, 47] . Regarding AD, it was reported that selective CB2 agonists were able to prevent memory deficits in Ab-injected rats and mice [48] . Moreover, a specific role for the CB2 receptor in the modulation of tau phosphorylation was also suggested in APP/PS1 mice [49] . Recently, a novel cerebral role for CB2 receptors has been found, demonstrating that the activation of CB2 receptors increased brain glucose uptake in a murine model of AD [50] . Furthermore, CB2 agonists are devoid of psychoactive adverse effects associated with CB1 receptor activation [51] .
In this study, we assessed the effects of a novel dual CB2 agonist and BuChE inhibitor, PGN33, [11] on the proliferation of lymphoblasts from patients with late-onset AD. The existence of systemic manifestations in subjects with AD is now widely accepted [52] . Abnormalities in metabolic and biochemical processes in the AD brain are also present in peripheral cells, such as fibroblasts and lymphocytes, from patients [53] . Thus, peripheral cells and particularly lymphocytes had been used often to study cellular or molecular alterations of pathological significance (see [54] for a review). Cell cycle-related events are now considered an important pathogenic mechanism for neurodegenerative disorders including AD, [29] with alterations observed in both neurons and peripheral cells [5, 55] . For these reasons, we found it interesting to evaluate the potential of drugs able to interfere with cell-cycle activation for AD treatment. We have evaluated the antiproliferative effects of a novel CB2 agonist, PGN33, on immortalized lymphocytes from patients with AD. Additionally, we have investigated the effects of PGN33 on Abinduced death of primary neuronal cultures, which is associated with cell-cycle reactivation in these post-mitotic neurons [44] . It is worth highlighting our previous work showing similar cell-cycle alterations in either EpsteinBarr virus-immortalized lymphocytes or freshly isolated lymphocytes from patients with AD [26, 27, 56] , indicating that cell-cycle control failure is an essential feature of AD pathogenesis that is not affected by the viral transformation. Therefore, lymphoblastoid cell lines from patients with AD could be useful as a suitable platform for testing novel therapies. Fig. 4 Effects of the CB2 agonist PGN33 on the phosphorylation status of pRb protein and levels of p27. Immortalized lymphocytes from control subjects and patients with Alzheimer's disease were seeded in the same experimental conditions as in Fig. 3 The CB2 agonist PGN33 efficiently blocked the serummediated enhancement of the proliferation characteristic of AD lymphoblasts, without significantly affecting the rate of proliferation of control cells. The concentration used in this work (5 lM) is in accordance with previous reports showing the effects of synthetic cannabinoid agonists in immune cells [57] . The PGN33 effect was not the result of increased cell death as this drug did not change the percentage of cells showing hypodiploid nuclei when the cellcycle status was analyzed. The effect of PGN33 was blocked by the CB2 receptor antagonist AM630, indicating its dependency on receptor activation.
Because we had previously reported a Ca 2? /CaM-dependent overactivation of PI3K/Akt, leading to increased phosphorylation of pRb protein, [27] we sought to investigate the effects of PGN33 on the phosphorylation status of CaMKII, Akt, and pRb. Treatment of AD cells with PGN33 prevented the previously reported upregulation of phosphorylated CaMKII, Akt, and pRb. The higher phosphorylation of the pRb protein observed in AD lymphoblasts resulted from diminished levels of the CDK inhibitor p27 [26, 27] . Here, we show that PGN33 was indeed capable of restoring p27 levels up to values found in control cells. Figure 6 shows schematically the proposed 0 -deoxyuridine for 4 h. DNA synthesis was assessed by 5-bromo-2 0 -deoxyuridine incorporation method according to the manufacturer's instructions. *p \ 0.05 significantly different from untreated cells; p \ 0.01 significantly different from Ab-treated cells. e Rat cortical primary neurons were incubated in the absence or presence of 5 lM Ab for 24 h and then harvested to prepare cell lysates to determine pRb and p27 levels by western blotting. Representative immunoblots are presented. ppRb hyperphosphorylated pRb scenario. Activation of CB2 receptors prevented the Ca 2? / CaM-induced overactivation of PI3K/Akt pathway, which in turn restored the levels of p27, reducing CDK activity and cell-cycle activation. The effect of PGN33 preventing the phosphorylation of Akt is in line with previous reports indicating similar effects of CB2 synthetic agonists in blocking the epidermal growth factor-induced activation of Akt in non-small-cell lung cancer [58] . The molecular mechanism involved in the effect of PG33 preventing the overactivation of CaM-dependent activation of PI3K/Akt cannot be ascertained with the present data. However, this blockage may result from changes in the activity of the Src family of tyrosine kinases induced by CB2 signaling [59, 60] . Phosphorylation of CaM at Tyr99 by a Src kinase is required for CaM binding to the p85 subunit and subsequent PI3K activation [61] . Changes in the proliferative activity and state of activation of PI3K/Akt and CaMKII in AD lymphoblasts did not correlate with disease severity as PGN33 was equally effective in cell lines derived from patients with early or advanced disease. These observations may indicate the cell disturbances reported here are early manifestations of the disease, in good agreement with the cell-cycle theory, which states that neurodegeneration, induced by cell-cycle activation, is an early feature in the instigation of the disease [62] .
Butyrylcholinesterase activity was reported to be increased in the AD brain and associated with the loss of episodic memory [63] and Ab burden [64] . However, the effect of PGN33 seems to be independent of its ability to inhibit BuChE activity, as PGN154, a BuChE-specific inhibitor without CB2 agonist capacity, had no effect on the proliferation of lymphoblasts. Further work analyzing the effects of this compound in animal models of AD will help to assess if its inhibiting BuChE activity conveys any additional potential for AD management.
Although alterations detected in peripheral cells from patients might not fully reflect those occurring in the AD brain, it may be worthwhile mentioning that an increased phosphorylation of Akt in AD temporal cortex neurons [65] was associated with increased levels of Akt substrates and lower levels of p27 protein [66] . Similarly, impaired CaMKII activation was also detected in the AD brain, associated with increased phosphorylation of tau and neurofibrillary tangle formation [67] . Moreover, PGN33 was able to partially prevent the cell-cycle activation and cell death induced by Ab in primary rat cortical neuronal cultures. PGN33 treatment reduced the Ab-induced increased levels of pRb phosphorylation and normalized the cellular content of p27. These results add further support to the hypothesis that cell-cycle control failure underlies neuronal /calmodulin (CaM)-dependent activation of PI3K/Akt, normalized the cellular content of p27, and restored normal rates of pRb phosphorylation and cell-cycle activation. ER endoplasmic reticulum, PTX pertussis toxin loss and indicate the usefulness of lymphoblasts from patients with AD to study molecular events linked to AD etiopathogenesis.
However, the activation of CB2 receptors in cells of the immune system might also have beneficial effects on AD, as systemic inflammation is known to play an important role in the instigation and progression of AD [52] . CB2 receptors are highly expressed in lymphocytes [13] ; therefore, their activation could contribute to ameliorate the proinflammatory cytokine production [68] . Moreover, it has been reported that the CB2 agonist JWH-015 was able to protect and rescue peripheral blood lymphocytes from Ab-and H 2 O 2 -induced apoptosis [69] . Altogether, these observations add further support to the idea that CB2 agonists could have neuroprotective effects in AD. Our findings suggest that PGN33, acting through a CB2 receptor-mediated mechanism, deserves further studies to establish its potential in the therapy of AD.
Conclusions
Our results suggest that CB2 receptors could be a pharmacological target for AD treatment. PGN33, a novel indazole derivative, acting through CB2 receptor-dependent mechanism was capable of normalizing proliferation and signaling of AD lymphoblasts and showed neuroprotective effects in neuronal cells. Therefore, PGN33 can be considered a promising drug candidate for novel treatment of AD.
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